Overview

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the pharmacokinetics of darapladib and its metabolites following single and 28 days of repeat dosing of darapladib.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Darapladib